NOVN Research & Analysis Hub

The 1Q26 reporting season for European Pharma and Biotech has revealed a robust financial landscape, with revenue beat rates reaching 40% and earnings beats at 70%. For a major sector constituent like Novartis, the current 10% valuation discount of the industry relative to the European market presents a significant context for investment analysis. Research emphasizes that the industry is entering a critical phase where innovation leadership is the primary differentiator for long-term success. Strategic focus is increasingly placed on companies that can demonstrate outsized growth potential to offset significant Loss of Exclusivity (LoE) challenges projected into the 2030s. In this environment, the momentum of internal innovation and the execution of strategic M&A are identified as vital components for sustaining market position. Goldman Sachs’ selective approach highlights the importance of being positioned within companies that possess strong R&D pipelines and defensive growth characteristics. Ultimately, the research direction for Novartis and its peers suggests that navigating the upcoming decade will require a disciplined balance of earnings growth and proactive portfolio management.